RecruitingNCT03253536

Prospective Observational Trial to Evaluate Quality of Life After Stereotactic Ablative Radiation Therapy in Patients With Hepatocellular Carcinoma


Sponsor

Ludwig-Maximilians - University of Munich

Enrollment

100 participants

Start Date

Jul 10, 2017

Study Type

OBSERVATIONAL

Conditions

Summary

Prospective single arm, single center observational study to evaluate Quality of Life (Qol) after stereotactic body radiotherapy for patients with hepatocellular cancer. Patients will receive work-up, treatment and follow-up exclusively as routinely done except additional quality of life measurements. Qol will be measured by standardized and validated EORTC questionaires at different time points during routine follow-up.


Eligibility

Min Age: 18 Years

Inclusion Criteria6

  • histologically or radiologically proven hepatocellular carcinoma
  • lesions suitable for stereotactic radiation therapy
  • indication for SBRT according to multidisciplinary board evaluation
  • age \>= 18 years
  • written informed consent for study participation
  • mental and verbal ability to complete standardized questionaires according to assessment by investigator (physician)

Exclusion Criteria8

  • age \< 18 years
  • prior HCC specific systemic therapy
  • concurrent oncological systemic treatment
  • distant metastases
  • inadequate ability tobe compliant with the protocol or to complete standardizes questionaires
  • inability to receive contrast-enhanced planning CT
  • missing ability to give informed consent
  • legal custody

Interventions

OTHERobservational

none (observational study)


Locations(1)

Department of Radiation Oncology, University Hospital, LMU Munich

Munich, Bavaria, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03253536


Related Trials